ScreenerHero

COCPCocrystal Pharma, Inc.

NAS · US · Healthcare · Biotechnology · cocrystalpharma.com
1.150USD+0.44%Mkt Cap: 22.15M $P/E: —

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap22.15M $
Enterprise Value21.71M $
Revenue (TTM)330.00K $
Gross Profit-4.72M $
Net Income (TTM)-8.83M $
Revenue/Share0.0250 USD
Last Price1.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS19188J4094
Valuation
P/E (Trailing)—
P/E (Forward)-2.02
PEG—
EV/EBITDA-2.16
EV/Revenue65.79
P/S68.30
P/B3.91
EPS (TTM)-0.77
EPS (Forward)-0.58
52W Range
0.760020% of range2.670
52W High2.670 USD
52W Low0.7600 USD
Profitability
Gross Margin0.00%
Oper. Margin-3032.38%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-139.49%
ROA-90.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.19M $
CapEx (TTM)12.00K $
FCF Margin-1311.74%
FCF Yield-19.54%
Net Debt-828.00K $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.24
Current Ratio1.24
Quick Ratio1.11
Book Value/Sh0.2990 USD
Cash/Share0.1130 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 24, 2018
Splits
Last Split1:12
Split DateOct 11, 2022
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Upside (mean)+682.6%
Target Range8.000 USD – 10.00 USD
$8.000+682.6% to mean$10.00
# Analysts2
Ownership
Shares Out.19.26M
Float11.85M
Insiders65.71%
Institutions5.77%
Short Interest
Short Ratio13.7d
Short % Float3.75%
Short % Out.2.81%
Shares Short388.00K
Short (prev mo.)404.50K
Technical
SMA 501.002 (+14.8%)
SMA 2001.084 (+6.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)58.30K
Avg Vol (10d)82.32K
Technical Indicators
RSI (14)66.5
MACD0.0420
MACD Signal0.0223
MACD Hist.+0.0197
BB Upper1.215 USD
BB Middle1.007 USD
BB Lower0.7996 USD
BB Width41.24%
ATR (14)0.0697 USD
Vol Ratio (20d)1.16x